Logo Tafalgie Therapeutics

approach & actual context

the prevention & treatment of chronic and acute pain

Preclinical studies have demonstrated that TAFA4 has considerable potential as an analgesic for the treatment of chronic postoperative and neuropathic pain. 

Pain, whether chronic or acute, is a frequent condition that is challenging to treat. A lack of effective treatment is an important sociological issue with implications for the well-being of patients. Moreover, chronic pain can be debilitating and has a major effect on the morale of patients, rendering them more susceptible to depression.


Chronic postoperative pain (CPOP) is of major economic and societal concern due to the high healthcare costs and rates of absenteeism it generates.

A mean of one in five patients develop Chronic postoperative pain after surgery. About 500,000 people per year suffer from Chronic postoperative pain in France, and this condition has a significant impact on the quality of life of these patients. Chronic postoperative pain remains poorly understood and is underdiagnosed, and is therefore a major problem for healthcare systems.

Chronic postoperative pain can occur in 10 to 50% of patients undergoing surgery, with 2 to 10% suffering from acute pain.

Chronic postoperative pain is one of the principal reasons for consultations at pain control centers. Amputation, breast cancer, and thoracic and herniated disc operations are the most likely causes of induced chronic pain. After lumbar pain, surgery is the second most common cause of neuropathic pain in the general population.


millions surgical interventions are performed around the world each year.

0 %

people Chronic pain occurs in a mean of 20% of those undergoing surgery and is one of the major motives for consulting at a pain clinic.

Neuropathic Pain

Neuropathic pain is characterized by unpleasant symptoms, such as shooting pain or burning sensations, numbness, altered sensations and sensations that are very difficult to describe.

According to the International Association for the Study of Pain, neuropathic pain results directly from injury or disease affecting the somatosensory system. There is no effective long-term treatment for many patients with neuropathic pain, with some cases proving refractory to the most powerful analgesics, such as morphine . Antiepileptic drugs or antidepressants are the drugs most frequently prescribed, despite their known adverse effects.

According to the STOPNEP (Study of the Prevalence of Neuropathic Pain) epidemiological survey performed in France (source: Livre Blanc de la Douleur), the prevalence of neuropathic pain in the general population is 7% in France, and this pain is moderate to severe in 5%.

0 %

Unpleasant pain or burning sensations are experienced by 8% of the world population.

0 %

Moderate-to-severe neuropathic pain affects 5% of the population.

our PIPELINE & key phases

Discover the key milestones in the progress of the Tafalgie project

alain eschalier

Professor Emeritus
Professor Emeritus at the University of Aix Marseille and former Professor at McGill University, Montreal, Canada

Alain Eschalier (MD, PhD, PharmD) is Professor Emeritus of Medical Pharmacology at the University of Clermont, Auvergne, France and is board-certified in pharmacology, psychiatry and human biology.


  • He is also the former head of the Medical Pharmacology Department of the Faculty of Medicine and the University Hospital of Clermont-Ferrand.
  • He was the founding director of several Inserm research units focusing on the fundamental and clinical pharmacology of pain, participated in the creation of two start-up companies and was a consultant for several companies.
  • He has chaired the Analgesia Institute since 2014, and has chaired the biomedical and public health research committee (CRBSP) and the scientific council of the French Society of Pharmacology and Therapeutics (SFPT) since 2015.
Eschalier is investigating the preclinical and clinical pharmacology of analgesics and the pathophysiology of chronic pain.

Clifford j.woolf

Professor of Neurology & neurobiology
Dr. Clifford J. Woolf is Professor of neurology and neurobiology at Harvard Medical School (HMS) and Director of the F.M Kirby Neurobiology Center at Boston Children’s Hospital. His work has greatly contributed to our understanding of pain.

Dr. Clifford J. Woolf was born in South Africa, where he earned his MB, BCh, and PhD degrees. He then moved to London and became Professor of Neurobiology at University College London. In 1997, he was recruited by the Massachusetts General Hospital and Harvard Medical School to serve as the Richard J. Kitz Professor of Anesthesiology Research. 

  • In 2010 he was named Director of the F. M. Kirby Neurobiology Center at Boston Children’s Hospital and became Professor of Neurology and Neurobiology at HMS. He holds faculty positions at both the Department of Neurobiology at Harvard Medical School and the Harvard Stem Cell Institute. Over his career, Dr. Woolf has received many honors and prizes. 


  •  In 2020, he was elected a fellow of the American Academy of Arts and Sciences and was received an honorary degree from the University of Lausanne, Switzerland. He received a Gill Distinguished Scientist award and the Reeve-Irvine medal in 2017, the Kerr award from the American Pain Society in 2015.
  • Woolf was appointed to the Board of Scientific Councilors of the National Institute of Neurological Diseases and Stroke from 2015 to 2019 and is currently a member of the NIH HEAL Partnership Committee for the development of new treatments for pain and addiction. He has published over 300 research papers on molecular, cellular, and systems neurobiology and has a portfolio of more than 30 issued patents. 

His research focuses on the roles of the functional, chemical and structural plasticity of neurons in both the normal adaptive functions of nervous systems and in the maladaptive changes contributing to neurological diseases. He focuses, in particular, on pain, regeneration and neurodegeneration and on the exploitation of stem cell-derived neurons for disease modeling and drug screening.

Jean-louis kraus

Professor Emeritus
Professor Emeritus at the University of Aix Marseille and former Professor at McGill University, Montreal, Canada

Jean-Louis Kraus is Professor Emeritus at the University of Aix Marseille, France and was formerly Professor at McGill University in Montreal, Canada.

  • He has an extensive experience in the creation of biotechnology start-ups, such as Trophos (which was acquired by Roche, Switzerland), BioPharmed and Planktovie. 
  • His international reputation in medicinal chemistry has resulted in his invitation to serve as a member of numerous scientific research evaluation committees (Inserm, FRM, Sidaction, ANRS) in France and abroad, and as a senior scientist at Biochem Pharma (Canada). He has also served as a member of various advisory committees for strategic private investments and was responsible for research & development as a member of the Board of Marseille University (creation of Protisvalor).

Prof. Kraus’s considerable experience and commercial success have enabled him to develop extensive networks during the course of his career.

Jon levine

Jon David Levine is an American neuroscientist known for his research on pain and analgesia, particularly in the area of placebo studies. He is Professor of medicine, oral and maxillofacial surgery, and neurosciences at the University of California, San Francisco (UCSF).

• Prof. Levine’s research focuses on pain and analgesia, including, in particular, the mechanism by which the placebo effect can relieve pain. In 1978, he published an influential study showing that placebo analgesia could be blocked by the opioid antagonist naloxone.

Levine’s studies were the starting point for “placebo biology”.

ardem patapoutian

Honorary President
Ardem Patapoutian is a molecular biologist specializing in sensory transduction.

His research has led to the identification of new ion channels and receptors activated by temperature, mechanical force, and increases in cell volume. His laboratory has shown that these ion channels play crucial roles in sensing temperature, touch, and pain, in proprioception, and in regulating vascular tone.

Patapoutian was born in Lebanon in 1967 and attended the American University of Beirut for one year before emigrating to The United States in 1986. He became a US citizen, graduating from UCLA in 1990 and obtaining a PhD from Caltech in 996, for his work in the laboratory of Dr. Barbara Wold.

Following his postdoctoral work with Dr. Lou Reichardt at UCSF, he joined the Scripps Research Institute faculty in 2000, and is currently Professor in the Department of Neuroscience. He also held a position at the Genomics Institute of The Novartis Research Foundation from 2000-2014.

Patapoutian was awarded the Young Investigator Award from the Society for Neuroscience in 2006 and was named an Investigator of the Howard Hughes Medical Institute in 2014.

He is a fellow of the American Association for the Advancement of Science (2016), a member of the National Academy of Sciences (2017) and a member of the American Academy of Arts and Sciences (2020). He received the 2017 Alden Spencer Award from Columbia University (together with David Ginty), the 2019 Rosenstiel Award for Distinguished Work in Basic Medical Research (with David Julius), the 2020 Kavli Prize in Neuroscience (with David Julius), the 2021 BBVA Foundation Frontiers of Knowledge Award (shared with David Julius), and the 2021 Nobel Prize in Physiology or Medicine (with David Julius).

2021 : Nobel Prize in Physiology or Medicine (with David Julius)